Dopamine D2 receptor inhibition of adenylyl cyclase is abolished by acute ethanol but restored after chronic ethanol exposure (tolerance).
Dopamine D2 (D2) receptors seem to mediate reinforcing responses to addicting drugs. A stably transfected NG108-15 cell line expressing the long form of the rat brain D2 receptor (D2L) was used to determine how ethanol modifies D2 receptor coupling to adenylyl cyclase. Activation of D2L receptors by the D2 receptor-specific agonist R-(-)-2,10,11-trihydroxy-N-propylnorapomorphine hydrobromide (NPA) inhibits both basal and receptor-stimulated cAMP production in these cells. Ethanol added acutely prevents D2L receptor inhibition of cAMP production. After chronic exposure to ethanol, however, D2L receptor coupling to adenylyl cyclase becomes tolerant to rechallenge with ethanol, i.e., ethanol no longer inhibits D2L receptor coupling and NPA inhibition of cAMP production is restored. Acute ethanol does not change NPA binding to D2 receptor in cell membranes but abolishes guanosine-5'-O-(3-thio)triphosphate induction of a lower-affinity state; chronic ethanol is without effect. The protein kinase A (PKA) inhibitor adenosine 3',5' cyclic monophosphorothioate, Rp-isomer, prevents acute ethanol inhibition of D2L receptor coupling. In contrast, the PKA activator adenosine 3',5' cyclic monophosphorothioate, Sp-isomer, reverses chronic ethanol-induced tolerance of D2L receptor coupling, restoring coupling to an ethanol-sensitive state. These results suggest that D2L receptor coupling to adenylyl cyclase via G(i) develops tolerance to ethanol inhibition, which appears to be influenced by PKA activity.
Yao
L
L
Ernest Gallo Clinic and Research Center, University of California, San Francisco, California, USA.
Asai
K
K
Jiang
Z
Z
Ishii
A
A
Fan
P
P
Gordon
A S
AS
Diamond
I
I
D000067956:Adenylyl Cyclase Inhibitors; D000262:Adenylyl Cyclases / Q000494:pharmacology*; D002460:Cell Line; D002492:Central Nervous System Depressants / Q000494:pharmacology*; D017868:Cyclic AMP-Dependent Protein Kinases / Q000378:metabolism; D065127:Dopamine D2 Receptor Antagonists; D004361:Drug Tolerance; D004791:Enzyme Inhibitors / Q000494:pharmacology; D000431:Ethanol / Q000494:pharmacology*; D019204:GTP-Binding Proteins / Q000378:metabolism; D006801:Humans; D043588:Receptor, Muscarinic M4; D011976:Receptors, Muscarinic / Q000187:drug effects; D017465:Receptors, Opioid, delta / Q000819:agonists
D000067956:Adenylyl Cyclase Inhibitors; D002492:Central Nervous System Depressants; D065127:Dopamine D2 Receptor Antagonists; D004791:Enzyme Inhibitors; D043588:Receptor, Muscarinic M4; D011976:Receptors, Muscarinic; D017465:Receptors, Opioid, delta; D000431:Ethanol; D017868:Cyclic AMP-Dependent Protein Kinases; D019204:GTP-Binding Proteins; D000262:Adenylyl Cyclases